Kardigan, a clinical‑stage biotechnology company headquartered in Princeton, New Jersey, disclosed its intention to pursue an initial public offering in the United States. The IPO targets a maximum enterprise valuation of $1.4 billion. To achieve this, the company plans to raise up to $373.3 million by issuing 23.3 million shares at a price range of $14 to $16 per share. The offering will be underwritten by J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen. Upon completion, Kardigan’s shares will be listed on the Nasdaq exchange under the ticker symbol “KARD”.
In parallel with the capital‑raising effort, Kardigan highlighted its pipeline of three late‑stage experimental precision medicines aimed at cardiovascular diseases: (i) danicamtiv, designed for patients with genetic dilated cardiomyopathy; (ii) ataciguat, targeting calcific aortic valve stenosis; and (iii) tonlamarsen, which inhibits hepatic angiotensinogen to manage blood pressure in acute severe hypertension. These therapeutic candidates represent the company’s core scientific focus as it seeks to commercialize novel cardiovascular treatments.
The combination of a sizable valuation target, a substantial capital raise, and a robust late‑stage pipeline underscores Kardigan’s strategic positioning as it enters the public markets.